NEW YORK (GenomeWeb News) – Protein Sciences has licensed its FluBiok recombinant influenza vaccine to Japanese biotech UMN Pharma to make and sell the product in that market.
Â
Terms of the deal call for PSC to transfer technology to UMN, which will register, manufacture, market, and sell the vaccine in Japan for annual and pandemic use.
Â
One the test is registered with Japanese regulators, UMN will buy commercial quantities of FluBiok from PSC until a commercial manufacturing facility is available in the country.
Â
The license terms include a multimillion-dollar upfront payment and double-digit royalties, PSC said.
Â
FluBiok has received "accelerated approval" status from the US Food and Drug Administration and PSC said it expects to file a Biologics License Application with the agency in early 2007.